CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This research focuses on developing new small molecules as potential treatments for asthma, inspired by a natural product. These compounds aim to inhibit specific protein interactions involved in allergic responses, offering a more sustainable alternative to existing therapies like monoclonal antibodies.
The incidence of allergic disease, from hay fever to asthma and anaphylactic shock, is increasing world-wide, nowhere more than in the UK where it has risen three-fold in 20 years and is now the highest in the world.
Allergies including asthma afflict 40% of the UK population and bronchial asthma currently affects 5.2 million.
The yearly cost to the UK National Health System in primary care alone exceeds €1,200M, and the loss of 18 million working days costs a further €1,400M.
The quality of lif…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
